| Website | hybrigenics.com |
| Category | BioTech |
| Phone | +33 1 5810 3800 |
| Employees | |
| Description | biotechnology company |
| Unattributed, 9/09 Yorkville Advisors | $7.32M |
Hybrigenics S.A., a biotechnology and pharmaceutical company, focuses on therapeutics against cancer and commercializing its technology and bioinformatics platforms to identify, validate, and inhibit protein interactions. It is developing a program based on inecalcitol, a vitamin D analogue, for prostate cancer in combination with reference treatments. The company’s research program explores the role of Ubiquitin-Specific Proteases (USPs) in the degradation of onco-proteins, and the use of proprietary USP inhibitors against various cancer types. Hybrigenics offers an access to its Yeast-Two Hybrid (Y2H) screening platform, to its bioinformatics set of tools and database, and to its chemical library and small molecule screening platform, as fee-for-service activities. The company is headquartered in Paris, France.
